Paul Ridker, MD, MPH

All posts by Paul Ridker, MD, MPH

RSS

October 3rd, 2012

CRP and Cholesterol Emerge as Equally Strong Predictors of Cardiovascular Risk

Paul Ridker discusses findings from the Emerging Risk Factors Collaboration showing that C-reactive protein provides incremental risk information comparable to that of total cholesterol and HDL cholesterol.


August 30th, 2012

Low-Dose Methotrexate to Prevent Recurrent MI and Stroke?

Paul Ridker discusses the Cardiovascular Inflammation Reduction Trial, which will formally test the inflammatory hypothesis.


January 28th, 2011

Does CRP Level Modify the Benefit of Statins? Paul Ridker Reacts to New Data

CardioExchange welcomes Paul M. Ridker, a leading researcher on the value of C-reactive protein (CRP) concentration as a prognostic marker of cardiovascular risk, to respond to the latest data on CRP and statin therapy from the Heart Protection Study (HPS). The New HPS Findings on CRP: The HPS investigators sought to determine whether statin therapy might […]